Prominent Companies - U.S. P2Y12 Inhibitors Industry

 

Over the course of the forecast period, the U.S. P2Y12 Inhibitors market is anticipated to increase due to the rising prevalence of cardiovascular illnesses in the country. For instance, it is anticipated that heart disease is the number one killer among men, women, and members of the majority of racial and ethnic groups in the United States, according to data from the Centres for Disease Control and Prevention published in September 2021. In addition, around 659,000 Americans pass away from heart disease each year.

The market for P2Y12 Inhibitors in the United States is anticipated to reach around US $ 215.7 Mn in 2021 and is projected to grow at a CAGR of 3.8% from 2021 to 2028.

Leading Companies in the U.S. P2Y12 Inhibitors Industry:

1. Mylan N.V.:

Created to satisfy the rising need for potent medications, generic pharmaceutical goods are developed and manufactured. Built in 1961. With its corporate headquarters in the United Kingdom, Mylan and Upjohn, a division of Pfizer, will merge to become a new champion for global health that is specially positioned to meet the demand for medicine around the globe.

2. Bristol-Myers Squibb:

Bristol-Myers Squibb finds, creates, and sells medications for a range of therapeutic areas, including immunological, cancer, and cardiovascular illnesses. Bristol is a leader in drug discovery and has immuno-oncology as one of its main areas of concentration. Established in 1887.  Headquarter offices in New York, USA. Turning Point Therapeutics is now part of Bristol Myers Squibb, broadening its portfolio of precision oncology products.

3. Dr Reddy's Laboratories:

Dr. Reddy's Laboratories, which has its headquarters in India, creates and produces generic pharmaceuticals that are sold all over the world. The business specialises in active pharmaceutical ingredients and generic small-molecule pharmaceuticals that are inexpensive and simple to create. Incorporated in 1984. Hyderabad, Telangana, serves as the headquarters. The U.S. Generic Prescription Product Portfolio of Mayne Pharma will be acquired by Dr. Reddy's Laboratories, according to a statement.

4. Teva Pharmaceuticals USA, Inc.:

The business produces, markets, develops, and distributes generic drugs, novel pharmaceuticals, and biopharmaceuticals along with its affiliated and subsidiary businesses. Established in 1901. Headquarters at Israel's Petah Tikva.

5. AstraZeneca, Genentech:

AstraZeneca was created in 1999 through the union of the Swedish company Astra with the British company Zeneca Group. The company sells branded medications in a number of important therapeutic categories, including those for gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Nearly one-third of its sales originate from the United States, which is one of the largest foreign markets. AstraZeneca intends to expand after 2025 by strengthening its pipeline of innovations.

6. Eli Lilly and Company:

Eli Lilly and Company: Eli Lilly is a pharmaceutical company that specialises in immunology, oncology, neuroscience, and endocrinology. Verzenio for cancer, Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes, Taltz, and Olumiant for immunology are some of Lilly's most important pharmaceuticals. Founded in 1975. United States city of Indianapolis. The purchase expands upon a prior co-promotion agreement, wherein Sanofi lent its commercialization clout.

7. Cipla:

Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the anti-retroviral, CNS, urology, cardiology, anti-infective, respiratory, and various other key therapeutic segments. Founded in 1935. Headquarters at Mumbai, Maharashtra. Latest acquisition is Endura.

*Definition:

P2Y12 receptor blockers are another group of antiplatelet drugs. This group of drugs includes: clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor.